Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19264528 | 0.89 | CYP1A2 (0.56) | CYP1A2PAOXACHEGAACPB2 | |
| SCHEMBL838165 | 0.88 | DNM1 (0.49) | CYP1A2ALDH1A1TSHRKDM5ADNM1 | |
| SCHEMBL27705199 | 0.87 | LMNA (0.47) | CYP1A2PAOXACHEALDH1A1ALOX15 | |
| SCHEMBL5496454 | 0.85 | CYP1A2 (0.39) | CYP1A2GAAALOX5ALDH1A1ALOX15 | |
| SCHEMBL16938702 | 0.82 | PRSS1 (0.37) | CYP1A2GAAALOX5ALDH1A1ALOX15 | |
| SCHEMBL20880020 | 0.81 | ALDH1A1 (0.44) | CYP1A2GAAALOX5ALDH1A1CYP3A4 | |
| SCHEMBL18707721 | 0.81 | KDM5A (0.55) | GAAALDH1A1TSHRKDM5ADNM1 | |
| SCHEMBL2967294 | 0.80 | CYP1A2 (0.83) | CYP1A2PAOXGAACPB2ALDH1A1 | |
| SCHEMBL4915851 | 0.80 | CYP1A2 (0.83) | CYP1A2PAOXGAACPB2ALDH1A1 | |
| SCHEMBL3284074 | 0.80 | CYP1A2 (0.83) | CYP1A2PAOXGAACPB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 897 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260002155-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | ALNYLAM PHARMACEUTICALS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250171785-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | BANK OF AMERICA, N.A. | 2025-05-29 | — | — | US | disclosed |
| US-12227744-B2 | Compositions and methods for inhibiting expression of transthyretin | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240401060-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240327834-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240093199-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | ALNYLAM EUROPE AG (DE) | 2024-03-21 | — | — | US | disclosed |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | BANK OF AMERICA, N.A. | 2006-05-18 | — | — | US | disclosed |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | BANK OF AMERICA, N.A. | 2006-05-04 | — | — | US | disclosed |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | ALNYLAM PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006032041-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI-APOPTOTIC GENES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058266-A1 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | BANK OF AMERICA, N.A. | 2006-03-16 | — | — | US | disclosed |
| WO-2006020768-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1620544-A2 | MODIFIED iRNA AGENTS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005115481-A2 | NUCLEASE RESISTANT DOUBLE-STRANDED RIBONUCLEIC ACID | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058266-A1 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | NSUN2, RNMT, RNGTT | CYP1A2 1552/4885PAOX 3013/4885ACHE 4479/4885 |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | APOB, LDLR, APOL1 | CYP1A2 4636/4885PAOX 2378/4885ACHE 4822/4885 |
| US-20240327834-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | SAAL1, APOB, SCARB1 | CYP1A2 3832/4885PAOX 2113/4885ACHE 3556/4885 |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | BAX, BCL2, API5 | CYP1A2 4861/4885PAOX 2920/4885ACHE 4708/4885 |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | GNAQ, GNAI1, GNAI2 | CYP1A2 4879/4885PAOX 3418/4885ACHE 4783/4885 |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | CYP1A2 4824/4885PAOX 3892/4885ACHE 4742/4885 |
| US-20240401060-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | EGFR, ERBB3, ERBB2 | CYP1A2 4876/4885PAOX 4386/4885ACHE 4845/4885 |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | TTR, RNGTT, RNASE1 | CYP1A2 4540/4885PAOX 3511/4885ACHE 3277/4885 |
| US-20240093199-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | PCSK9, PCSK7, RNASE1 | CYP1A2 4692/4885PAOX 1867/4885ACHE 2791/4885 |
| US-12227744-B2 | Compositions and methods for inhibiting expression of transthyretin | TTR, RNGTT, RNASE1 | CYP1A2 4540/4885PAOX 3511/4885ACHE 3277/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | CYP1A2 4167/4885PAOX 2049/4885ACHE 3818/4885 |
| US-20250171785-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | PCSK9, PCSK7, RNASE1 | CYP1A2 4692/4885PAOX 1867/4885ACHE 2791/4885 |
| US-20260002155-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, APOB, APOL1 | CYP1A2 3321/4885PAOX 4080/4885ACHE 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.